Selected publications Phase I and pharmacologic study of the specific matrix metalloproteinase inhibitor BAY 12-9566 on a protracted oral daily dosing schedule in patients with solid malignancies. Journal of Clinical Oncology. 2000 Academic Article GET IT Times cited: 77
